A Subset of VEGFR-TKIs Activates AMPK in LKB1-mutant Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36459496/
The mutation of tumor suppressor gene liver kinase B1 (LKB1) has a prevalence of about 20% in non-small cell lung cancer (NSCLC). LKB1-mutant lung cancer is characterized by enhanced aggressiveness and immune escape, and is associated with poor prognosis. Therefore, it is urgent to develop effective ...
Conclusions: This study discovered AMPK as an important off-target of apatinib, and elucidated different effects of this cluster of VEGFR-TKIs on AMPK. This finding can be the basis for the accurate and combined application of these drugs in clinic, and highlights the subset of VEGFR-TKIs including apatinib and anlotinib are potentially valuable in the treatment of LKB1-mutant NSCLC.